Oncocine manufactures precision mRNA vaccines for personalised cancer treatments based on individual tumour profiles using its ONVAC platform. The artificial intelligence-based platform conducts tumour analysis, mutation profiling, and vaccine design by integrating patient-specific mutation profiles, tumour microenvironment data, and immunogenicity predictions. It targets healthcare providers and cancer patients for immunotherapy applications. The company was founded in 2025 by Ishani Malhotra, who serves as CEO and director; she holds an MSc in Regenerative Medicine from the University of Edinburgh and previously founded Carcinotech, an oncology biotech that reached Series A funding stage. Oncocine participated in an accelerator/incubator program led by LvlUp Ventures in January 2026. Headquarters are located at 16 Carnbee Park in Edinburgh, United Kingdom.